Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2023 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Other Non-Current Liabilities of $1.6 million for Q4 2025, up 827.06% on a QoQ basis from $174413.0 in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.6 million for Q4 2025.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (changed N/A YoY) and the FY2025 annual result came in at $1.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $1.6 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $174413.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.6 million in Q4 2025 and bottomed at $68878.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 67.58 Mn | 67.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.62 Mn |
| Jun 30, 2025 | 174,413.00 |
| Dec 31, 2023 | 68,878.00 |